SUPRIYA — Supriya Lifescience Balance Sheet
0.000.00%
- IN₹59.81bn
- IN₹58.80bn
- IN₹6.96bn
- 83
- 11
- 90
- 70
Annual balance sheet for Supriya Lifescience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 923 | 2,339 | 1,640 | 795 | 799 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 740 | 1,158 | 1,409 | 1,681 | 1,915 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2,655 | 4,975 | 4,649 | 3,978 | 4,370 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,772 | 2,317 | 3,281 | 4,573 | 5,995 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 4,455 | 7,348 | 8,203 | 9,212 | 11,123 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,460 | 997 | 958 | 769 | 822 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,769 | 1,191 | 1,208 | 1,059 | 1,156 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 2,686 | 6,157 | 6,995 | 8,154 | 9,968 |
| Total Liabilities & Shareholders' Equity | 4,455 | 7,348 | 8,203 | 9,212 | 11,123 |
| Total Common Shares Outstanding |